NLRP3 and Alzheimer disease: Besides, sulforaphane was suggested to be a promising drug candidate for AD therapy, as it inhibits cathepsin B- and caspase-1-dependent NLRP3 inflammasome activation induced by amyloid-β (Aβ)274.